United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $572.61, for a total transaction of $5,726,100.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company's stock, valued at $10,808,586.36. This trade represents a 34.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
James Edgemond also recently made the following trade(s):
- On Monday, April 27th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $568.83, for a total transaction of $5,688,300.00.
- On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The shares were sold at an average price of $575.85, for a total transaction of $209,609.40.
- On Thursday, April 23rd, James Edgemond sold 9,636 shares of United Therapeutics stock. The shares were sold at an average price of $572.21, for a total transaction of $5,513,815.56.
- On Monday, April 20th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.86, for a total transaction of $5,778,600.00.
- On Thursday, April 16th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.18, for a total transaction of $5,771,800.00.
- On Monday, April 13th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $574.88, for a total transaction of $5,748,800.00.
- On Thursday, April 9th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.89, for a total transaction of $5,778,900.00.
- On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $558.40, for a total transaction of $5,584,000.00.
- On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $561.50, for a total transaction of $5,615,000.00.
- On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $593.17, for a total transaction of $5,931,700.00.
United Therapeutics Trading Down 0.2%
NASDAQ:UTHR opened at $570.40 on Friday. The stock has a market capitalization of $25.00 billion, a P/E ratio of 20.44, a price-to-earnings-growth ratio of 1.63 and a beta of 0.75. The firm has a 50 day moving average of $543.83 and a 200-day moving average of $497.42. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $607.89.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts' consensus estimates of $6.78 by $0.92. The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. United Therapeutics's revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter last year, the business posted $6.19 earnings per share. As a group, analysts forecast that United Therapeutics Corporation will post 27.97 EPS for the current fiscal year.
Institutional Trading of United Therapeutics
Institutional investors have recently bought and sold shares of the business. Torren Management LLC acquired a new stake in United Therapeutics during the 4th quarter worth $26,000. Activest Wealth Management grew its holdings in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 56 shares during the period. Entrust Financial LLC acquired a new stake in United Therapeutics during the 4th quarter worth $31,000. International Assets Investment Management LLC grew its holdings in United Therapeutics by 426.7% during the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 64 shares during the period. Finally, Wilmington Savings Fund Society FSB grew its holdings in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock worth $37,000 after acquiring an additional 49 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.
Analyst Upgrades and Downgrades
A number of brokerages recently weighed in on UTHR. UBS Group raised their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the company a "buy" rating in a report on Thursday, March 5th. HC Wainwright raised their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the company a "buy" rating in a report on Tuesday, March 31st. Cantor Fitzgerald raised their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an "overweight" rating in a report on Thursday, March 12th. Oppenheimer raised their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, February 26th. Finally, Raymond James Financial began coverage on shares of United Therapeutics in a report on Friday, April 10th. They issued an "outperform" rating and a $700.00 price target for the company. Ten equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, United Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $601.50.
Read Our Latest Stock Report on United Therapeutics
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
